EP4041245A4 - Formulations thérapeutiques et leurs utilisations - Google Patents

Formulations thérapeutiques et leurs utilisations Download PDF

Info

Publication number: EP4041245A4
Authority: EP; European Patent Office
Prior art keywords: therapeutic formulations; formulations; therapeutic
Prior art date: 2019-11-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP20883598.3A

Other languages

German (de)

English (en)

Other versions

EP4041245A1 (fr

Inventor

Douglas I. Hepler

Gail L. DEMPSEY

Roland Johnson

Michael Kelly

Michael Daniel

Neil E. Paulsen

Bert CLAYTON

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Dechra Veterinary Products LLC

Original Assignee

Piedmont Animal Health Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-11-01

Filing date

2020-10-29

Publication date

2023-12-13

2020-10-29 Application filed by Piedmont Animal Health Inc filed Critical Piedmont Animal Health Inc

2020-10-29 Priority to EP23174724.7A priority Critical patent/EP4233854A3/fr

2022-08-17 Publication of EP4041245A1 publication Critical patent/EP4041245A1/fr

2023-12-13 Publication of EP4041245A4 publication Critical patent/EP4041245A4/fr

Status Withdrawn legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

EP20883598.3A 2019-11-01 2020-10-29 Formulations thérapeutiques et leurs utilisations Withdrawn EP4041245A4 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP23174724.7A EP4233854A3 (fr)	2019-11-01	2020-10-29	Formulations thérapeutiques et leurs utilisations

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201962929631P	2019-11-01	2019-11-01
PCT/US2020/057899 WO2021087074A1 (fr)	2019-11-01	2020-10-29	Formulations thérapeutiques et leurs utilisations

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
EP23174724.7A Division-Into EP4233854A3 (fr)	2019-11-01	2020-10-29	Formulations thérapeutiques et leurs utilisations
EP23174724.7A Division EP4233854A3 (fr)	2019-11-01	2020-10-29	Formulations thérapeutiques et leurs utilisations

Publications (2)

Publication Number	Publication Date
EP4041245A1 EP4041245A1 (fr)	2022-08-17
EP4041245A4 true EP4041245A4 (fr)	2023-12-13

Family

ID=75715592

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP20883598.3A Withdrawn EP4041245A4 (fr)	2019-11-01	2020-10-29	Formulations thérapeutiques et leurs utilisations
EP23174724.7A Withdrawn EP4233854A3 (fr)	2019-11-01	2020-10-29	Formulations thérapeutiques et leurs utilisations

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP23174724.7A Withdrawn EP4233854A3 (fr)	2019-11-01	2020-10-29	Formulations thérapeutiques et leurs utilisations

Country Status (6)

Country	Link
EP (2)	EP4041245A4 (fr)
JP (1)	JP2023501207A (fr)
CN (2)	CN118750482A (fr)
AU (1)	AU2020375825A1 (fr)
CA (1)	CA3156590A1 (fr)
WO (1)	WO2021087074A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040147581A1 (en) *	2002-11-18	2004-07-29	Pharmacia Corporation	Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20040204471A1 (en) *	2003-03-20	2004-10-14	Pharmacia Corporation	Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
US20050070543A1 (en) *	2003-07-11	2005-03-31	Pharmacia Corporation	Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
US20140256804A1 (en) *	2011-10-18	2014-09-11	Raqualia Pharma Inc.	Pharmaceutical composition
US20190142789A1 (en) *	2017-08-09	2019-05-16	Piedmont Animal Health, Llc	Therapeutic formulations and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9804886D0 (en) *	1998-03-06	1998-04-29	Merck Sharp & Dohme	Therapeutic combination
US20040138296A1 (en) *	2002-08-12	2004-07-15	Pharmacia Corporation	Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease
US20040235925A1 (en) *	2002-12-17	2004-11-25	Pharmacia Corporation	Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
GT200600396A (es) *	2005-09-07	2007-04-23		Dispositivos para la aplicacion de medicamentos transdermicos conteniendo o-desmetil venlafaxina (odv) o sus sales
UA119324C2 (uk) *	2013-04-02	2019-06-10	Теміс Медікер Лімітед	Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
SG11201601304XA (en) *	2013-09-12	2016-03-30	Esteve Labor Dr	Nsaid and sigma receptor ligand combinations
WO2015066302A2 (fr) *	2013-10-30	2015-05-07	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Compositions, méthodes d'utilisation et méthodes de traitement
KR20170003527A (ko) *	2014-02-24	2017-01-09	유리젠 파마슈티컬스, 인코포레이티드	경구 투여용 펜토산 폴리설페이트 염의 조성물

2020
- 2020-10-29 AU AU2020375825A patent/AU2020375825A1/en active Pending
- 2020-10-29 CA CA3156590A patent/CA3156590A1/fr active Pending
- 2020-10-29 EP EP20883598.3A patent/EP4041245A4/fr not_active Withdrawn
- 2020-10-29 EP EP23174724.7A patent/EP4233854A3/fr not_active Withdrawn
- 2020-10-29 CN CN202410884200.1A patent/CN118750482A/zh not_active Withdrawn
- 2020-10-29 JP JP2022525194A patent/JP2023501207A/ja active Pending
- 2020-10-29 WO PCT/US2020/057899 patent/WO2021087074A1/fr not_active Ceased
- 2020-10-29 CN CN202080079622.1A patent/CN114728014A/zh active Pending

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040147581A1 (en) *	2002-11-18	2004-07-29	Pharmacia Corporation	Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20040204471A1 (en) *	2003-03-20	2004-10-14	Pharmacia Corporation	Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
US20050070543A1 (en) *	2003-07-11	2005-03-31	Pharmacia Corporation	Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
US20140256804A1 (en) *	2011-10-18	2014-09-11	Raqualia Pharma Inc.	Pharmaceutical composition
US20190142789A1 (en) *	2017-08-09	2019-05-16	Piedmont Animal Health, Llc	Therapeutic formulations and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021087074A1 *
ZARGHI AFSHIN ET AL: "Design, Synthesis, and Biological Evaluation of New 2-Phenyl-4H-chromen-4-one Derivatives as Selective Cyclooxygenase-2 Inhibitors", SCIENTIA PHARMACEUTICA, vol. 83, no. 1, 1 January 2015 (2015-01-01), Austria, pages 15 - 26, XP055932699, ISSN: 0036-8709, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727773/pdf/SciPharm-83-15.pdf> DOI: 10.3797/scipharm.1407-20 *

Also Published As

Publication number	Publication date
WO2021087074A1 (fr)	2021-05-06
EP4041245A1 (fr)	2022-08-17
EP4233854A2 (fr)	2023-08-30
CA3156590A1 (fr)	2021-05-06
CN118750482A (zh)	2024-10-11
JP2023501207A (ja)	2023-01-18
EP4233854A3 (fr)	2024-01-17
AU2020375825A1 (en)	2022-06-02
CN114728014A (zh)	2022-07-08

Legal Events

Date	Code	Title	Description
2021-05-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2022-07-15	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2022-07-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2022-08-17	17P	Request for examination filed	Effective date: 20220427
2022-08-17	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-02-08	DAV	Request for validation of the european patent (deleted)
2023-02-08	DAX	Request for extension of the european patent (deleted)
2023-08-03	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031600000 Ipc: A61K0009000000
2023-09-06	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 29/00 20060101ALI20230803BHEP Ipc: A61K 31/485 20060101ALI20230803BHEP Ipc: A61K 31/352 20060101ALI20230803BHEP Ipc: A61K 47/12 20060101ALI20230803BHEP Ipc: A61K 47/10 20170101ALI20230803BHEP Ipc: A61K 9/20 20060101ALI20230803BHEP Ipc: A61K 9/08 20060101ALI20230803BHEP Ipc: A61K 9/00 20060101AFI20230803BHEP
2023-12-13	A4	Supplementary search report drawn up and despatched	Effective date: 20231109
2023-12-13	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 29/00 20060101ALI20231103BHEP Ipc: A61K 31/485 20060101ALI20231103BHEP Ipc: A61K 31/352 20060101ALI20231103BHEP Ipc: A61K 47/12 20060101ALI20231103BHEP Ipc: A61K 47/10 20170101ALI20231103BHEP Ipc: A61K 9/20 20060101ALI20231103BHEP Ipc: A61K 9/08 20060101ALI20231103BHEP Ipc: A61K 9/00 20060101AFI20231103BHEP
2024-02-28	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: DECHRA VETERINARY PRODUCTS, LLC
2025-05-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
2025-06-11	18W	Application withdrawn	Effective date: 20250502

Publication	Publication Date	Title
EP3946320A4 (fr)	2022-12-28	Conjugués liés à hsp90 et formulations de ceux-ci
EP4110066A4 (fr)	2024-04-17	Formulations et leurs utilisations
EP3706741A4 (fr)	2022-03-30	Composition pharmaceutique et utilisation associée
EP3740576A4 (fr)	2021-10-20	Compositions thérapeutiques et leurs procédés de préparation et d'utilisation
EP4034159A4 (fr)	2024-02-21	Néoglycoconjugués utilisés en tant que vaccins et outils thérapeutiques
EP4011898B8 (fr)	2026-02-18	Dérivé de 3-hydroxy-5-pregnane-20-one et son utilisation
IL291543A (en)	2022-05-01	Medical preparations and their use
EP3980008A4 (fr)	2023-06-28	Formulations à libération modifiée et utilisations associées
EP4007590A4 (fr)	2023-08-30	Formulations comprenant du dihydrohonokiol
EP3746078A4 (fr)	2021-11-17	Formulations orales et utilisations de celles-ci
EP3760616A4 (fr)	2021-11-03	Composé de 4-méthyldihydropyrimidinone et son utilisation médicinale
EP3873446A4 (fr)	2022-08-03	Composés et compositions thérapeutiques
EP3999056A4 (fr)	2023-10-25	Combinaison pharmaceutique et son utilisation
EP3919472A4 (fr)	2022-11-09	Dérivé de dézocine et son utilisation médicale
EP4017589A4 (fr)	2023-09-20	Méthodes thérapeutiques et utilisations associées
EP4031179A4 (fr)	2023-10-04	Combinaison pharmaceutique et utilisation de celle-ci
EP4041245A4 (fr)	2023-12-13	Formulations thérapeutiques et leurs utilisations
HK40072796A (en)	2022-12-02	Therapeutic formulations and uses thereof
AU2019903285A0 (en)	2019-09-19	Selenosugars and Therapeutic Uses Thereof
HK40067230A (en)	2022-09-02	Therapeutic methods and uses thereof
AU2019903095A0 (en)	2019-09-12	Therapeutic Methods And Uses Thereof
HK40080132A (en)	2023-04-28	Novel formulations and methods
HK40081386A (en)	2023-05-19	Trehalose formulations and uses thereof
AU2019903504A0 (en)	2019-10-10	Imaging and therapeutic compositions
HK40077814A (en)	2023-03-17	Pharmaceutical combination and use thereof